Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function
Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed
Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed
View: Text | PDF
Research Article Endocrinology

Somatostatin receptor subtype 5 modifies hypothalamic-pituitary-adrenal axis stress function

  • Text
  • PDF
Abstract

Pituitary corticotroph somatostatin receptor subtype 5 (SSTR5) signals to inhibit adrenocorticotrophin (ACTH) secretion. As ACTH deficiency results in attenuated adrenal cortisol production and an impaired stress response, we sought to clarify the role of SSTR5 in modifying the hypothalamic/pituitary/adrenal (HPA) axis. We generated Tg HP5 mice overexpressing SSTR5 in pituitary corticotrophs that produce the ACTH precursor proopiomelanocortin (POMC). Basal ACTH and corticosterone were similar in HP5 and WT mice, while HP5 mice showed attenuated ACTH and corticosterone responses to corticotrophin releasing hormone (CRH). HP5 mice exhibited attenuated corticosterone responses upon a restraint stress test and inflammatory stress following LPS injection, as well as increased anxiety-like and depressive-like behavior on open field and forced swim tests. Pituitary corticotroph CRH receptor subtype 1 (CRHR1) mRNA expression and ACTH responses to CRH were also attenuated in HP5 mice. In AtT20 cells stably overexpressing SSTR5, CRHR1 expression and cAMP response to CRH were reduced, whereas both were increased after SSTR5 KO. In elucidating mechanisms for these observations, we show that SSTR5-induced miR-449c suppresses both CRHR1 expression and function. We conclude that corticotroph SSTR5 attenuates HPA axis responses via CRHR1 downregulation, suggesting a role for SSTR5 in the pathogenesis of secondary adrenal insufficiency.

Authors

Masaaki Yamamoto, Anat Ben-Shlomo, Hiraku Kameda, Hidenori Fukuoka, Nan Deng, Yan Ding, Shlomo Melmed

×

Figure 7

SSTR5 downregulates CRHR1 signaling via miRNA-449c.

Options: View larger image (or click on image) Download as PowerPoint
SSTR5 downregulates CRHR1 signaling via miRNA-449c.
(A) Heatmap represen...
(A) Heatmap representing expression of candidate miRNAs that might bind Crhr1 3′UTR in (lane 1) SSTR5-KO AtT20 cells, (lane 2) SSTR5-overexpressing AtT20 cells, and (lane 3) HP5 and WT mouse pituitaries. Asterisks identify 7 candidate miRNAs that showed similar trends of change similar in lane 2 and lane 3 and an opposite trend in lane 1. Candidate miRNA expression levels were analyzed by qPCR, and levels of each miRNA were normalized to endogenous U6 small nuclear RNA. (B) Crhr1 mRNA level measured in WT AtT20 cells (2.0 × 105 cells/well, n = 3) 48 hours after transfection with 200 nM miRNA inhibitors identified in A or scramble negative control. Chrh1 mRNA normalized to Gapdh and divided by the scramble control level. Experiments were repeated in quadruplicate, and representative results are shown. Nucleotide sequence of miRNA inhibitors is given in Supplemental Table 4. (C) Representative CRHR1 protein expression and quantitative densitometry analysis of receptor normalized to β-tubulin in WT AtT20 cells (n = 4) treated with miR-449c inhibitor. (D) CRH-stimulated ACTH levels measured by ELISA in the culture medium of whole pituitary glands (8.0 × 104 cells/well, n = 4 at each CRH concentration) collected from WT (n = 4) and HP5 (n = 6) mice. ACTH level (pg/ml) normalized to cell number (per 1,000 cells). Cells were transfected with 200 nM miR-449c inhibitor or scramble for 24 hours and treated with CRH for 120 minutes, and culture medium was collected. Y axis represents fold change in ACTH from respective CRH-untreated cells (NT). Each value represents the average of triplicate experiments. (E) miRNA-449c expression in AtT20 cells transfected with plasmid carrying miRNA-449c (pmR-449c) or empty plasmid (pmR-empty) normalized to endogenous U6 small nuclear RNA. Relative mRNA expression levels were normalized to Gapdh. Results represent the combination of 3 experiments performed in quadruplicate. (F) mRNA levels of indicated genes in AtT20 cells overexpressing miRNA-449c (pmR-449c) compared with cells expressing empty vector (pmR-empty). Results represent the combination of 3 experiments performed in quadruplicate. (G) SSTR5-KO#3 AtT20 cells transfected with pmR-449c or pmR-empty compared with similarly transfected WT cells for 48 hours and treated with increasing doses of CRH for 30 minutes, after which intracellular cAMP was measured by LANCE cAMP assay (8.0 × 104 cells/well, n = 4 for each CRH concentration). Y axis represents fold change in cAMP from control CRH-untreated cells (NT). Experiments were performed in triplicate. Results are presented as mean ± SEM. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; 2-tailed unpaired t test, (D and G) with Bonferroni correction.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts